ACKR3 and cancer: Basal motility of these cells was also reduced with VUN700 treatment, with a similar ~30% decrease in accumulated distance In both cancer cell lines VUN701 also affected basal motility (Fig. 6, Supplementary Fig. 12), which may be explained by long-term treatment associated with trapping ACKR3 on the plasma membrane, seen for all ACKR3 nanobodies over time (Fig. 4A).